Vu, Michelle
Ghosh, Sabyasachi
Umashankar, Kandavadivu
Weber, Laura
Landis, Christina
Candela, Ninfa
Chastek, Benjamin
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Article History
Received: 13 October 2022
Accepted: 14 March 2023
First Online: 25 March 2023
Declarations
:
: This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practice published by the International Society for Pharmacoepidemiology. This study used de-identified retrospective claims data from the Optum® Research Database, therefore no specific ethical approval was required.
: Not applicable.
: NC is an employee of Takeda Pharmaceuticals U.S.A., Inc. and has stock or stock options. SG is a former employee of Takeda Pharmaceuticals U.S.A., Inc. and has stock or stock options. KU is an employee of the University of Illinois, Chicago, IL, USA, supported by a Takeda Pharmaceuticals U.S.A., Inc. fellowship at the time of the study. BC and MV are employees of Optum and have stock or stock options. LW and CL are employees of Optum.